Please use this identifier to cite or link to this item: https://doi.org/10.1038/bjc.2011.287
DC FieldValue
dc.titleSequential expression of putative stem cell markers in gastric carcinogenesis
dc.contributor.authorWang, T.
dc.contributor.authorOng, C.W.
dc.contributor.authorShi, J.
dc.contributor.authorSrivastava, S.
dc.contributor.authorYan, B.
dc.contributor.authorCheng, C.L.
dc.contributor.authorYong, W.P.
dc.contributor.authorChan, S.L.
dc.contributor.authorYeoh, K.G.
dc.contributor.authorIacopetta, B.
dc.contributor.authorSalto-Tellez, M.
dc.date.accessioned2014-11-25T09:47:20Z
dc.date.available2014-11-25T09:47:20Z
dc.date.issued2011-08-23
dc.identifier.citationWang, T., Ong, C.W., Shi, J., Srivastava, S., Yan, B., Cheng, C.L., Yong, W.P., Chan, S.L., Yeoh, K.G., Iacopetta, B., Salto-Tellez, M. (2011-08-23). Sequential expression of putative stem cell markers in gastric carcinogenesis. British Journal of Cancer 105 (5) : 658-665. ScholarBank@NUS Repository. https://doi.org/10.1038/bjc.2011.287
dc.identifier.issn00070920
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/108538
dc.description.abstractBackground: Gastric carcinogenesis has been well documented in the step-wise histopathological model, known as Correa pathway. Several biomarkers including CD44, Musashi-1 and CD133 have been reported as putative stem cell (PSC) markers. Methods: We investigated expression of PSC markers CD44, Musashi-1 and CD133 in relation to gastric carcinogenesis and prognosis and chemoresponse. Immunohistochemistry staining was performed in gastric cancer (GC) clinical specimens representing different steps of the Correa pathway. Gastric cancer samples taken before and after neoadjuvant chemotherapy with docetaxel, cisplatin and capecitabine (DCX) were also evaluated for PSC marker expression. Results: We showed that the expression of three PSC markers was significantly elevated in GC relative to normal gastric mucosa (P0.001 for each marker). Precancerous lesions, including intestinal metaplasia and dysplasia, demonstrated increased expression of CD44 and Musashi-1. CD133 was predominantly expressed along the border between intramucosal carcinoma and connective tissue at later stages. High CD44 and CD133 expression showed prognostic value for worse patient survival (P0.014 and P0.019, respectively). A small number of tumours with high expression of CD44 and CD133 showed pathological response to DCX-based neoadjuvant chemotherapy. Conclusion: CD44 and Musashi-1 are frequently expressed in both premalignant gastric lesions and invasive GC, whereas CD133 expression is restricted mainly to neoplastic tissues. © 2011 Cancer Research UK All Rights Reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/bjc.2011.287
dc.sourceScopus
dc.subjectCD133
dc.subjectCD44
dc.subjectCorrea pathway
dc.subjectgastric cancer
dc.subjectMusashi-1
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1038/bjc.2011.287
dc.description.sourcetitleBritish Journal of Cancer
dc.description.volume105
dc.description.issue5
dc.description.page658-665
dc.description.codenBJCAA
dc.identifier.isiut000294207800010
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.